{"brief_title": "Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis", "brief_summary": "OBJECTIVES: I. Determine the effects of alendronate sodium on skeletal remodeling and bone mineral density of the hip and spine in children with high-turnover idiopathic juvenile osteoporosis.", "detailed_description": "PROTOCOL OUTLINE: Patients receive oral alendronate sodium weekly for 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.", "condition": ["Osteoporosis"], "intervention_type": ["Drug"], "intervention_name": ["Alendronate"], "description": ["Pill, 35mg or 70mg weekly, depending upon the body weight for 12 months."], "arm_group_label": ["1 Alendronate for 12 months"], "other_name": ["Fosamax"], "criteria": "Eligibility Criteria: - 5-14 years of age - Weight 20 kg or greater - History of one or more atraumatic fracture - Sexual development no greater than Tanner II - Osteoporosis by DXA (Diagnosis of high-turnover osteoporosis with no underlying cause (e.g., malignancy, hyperthyroidism, hyperparathyroidism, or vitamin D intoxication) Inclusion Criteria: - Male and female children with a history of one or more atraumatic fractures, or evidence of one or more compression fractures on radiographs of the spine (reduction of >20%). - Bone mineral density by DXA at 2 standard deviations (SD) below normal mean for age (Z-score at least 2 SD below normal mean at the lumbar spine or hip) - Parental consent (and patient assent after age 12 years) to participate in the study. - Sexual development at Tanner stage II or less (Prepubertal stage) - Weight 20kg and more Exclusion Criteria: - History of severe gastritis or reflux - Marked kyphoscoliosis or inability to sit or stand for at least 30 minutes. - Abnormalities of the esophagus that delay emptying (e.g., strictures or achalasia) - Hypersensitivity to bisphosphonates - Uncorrected hypocalcemia - History of gastric or duodenal ulcers - Renal dysfunction as indicated by serum Creatinine greater than 1.5 mg/dL - Liver dysfunction as indicated by serum SGPT greater than 2 times upper limit of normal for age or serum total bilirubin greater than 2.0 mg/dL - Diagnosis of osteogenesis imperfecta (including family history) or blue sclerae or deafness - Diagnosis of active rickets, osteomalacia, or bone alkaline phosphatase > 2 times normal for age - Severe gastritis or reflux - Pregnancy - Anorexia Nervosa - Prior/Concurrent Therapy\u2014 - Prior course of prednisone allowed - No concurrent prednisone except inhaled steroids - No concurrent high-dose glucocorticoids - No concurrent salmon calcitonin - No other concurrent bisphosphonates - No concurrent long-term anti-seizure medication", "gender": "All", "minimum_age": "5 Years", "maximum_age": "14 Years", "healthy_volunteers": "No", "keyword": "rare disease", "mesh_term": ["Osteoporosis", "Alendronate"], "id": "NCT00010439"}